ALEXANDRIA, VA USA (Press Release) - January 28, 2014 - Studies released today in advance of the 2014 Genitourinary Cancers Symposium reveal survival outcomes in multiple GU cancers and provide insights on the early termination of cancer clinical trials.
This year marks the 10th anniversary of the Symposium, which will be held January 30 – February 1 at the San Francisco Marriott Marquis.
Four key studies were presented in today’s presscast:
- Enzalutamide Improves Survival in Men with Metastatic Castration-Resistant Prostate Cancer:
Presented in full for the first time, results from the phase III PREVAIL study show that enzalutamide increases survival by 29 percent in men with metastatic castration-resistant prostate cancer and slows or stops cancer growth in 59 percent of patients, delaying the need for chemotherapy by 17 months.
- Long-Term Data Confirms Radiotherapy Plus Anti-Androgen Therapy Substantially Improves 10- and 15-Year Prostate Cancer Survival Rates:
An updated analysis of clinical trial data from the Scandinavian Prostate Cancer Group’s Study VII shows that the combination of radiotherapy and oral anti-androgen therapy more than halves the 10- and 15- year cancer-specific mortality rate for men with locally advanced prostate cancer.
- Common Drug Improves Survival in Hypertensive Patients with Metastatic Renal Cell Carcinoma:
A retrospective study shows that angiotensin system inhibitors (ASIs), medications commonly used for hypertension, improve survival by nine months for patients with metastatic renal cell carcinoma who also have high blood pressure.
- Early Termination Not Unique to Genitourinary Cancer Clinical Trials - Approximately One in Five Adult Cancer Clinical Trials Fails to Complete:
Analysis of data from Clinicaltrials.gov shows that the early termination of clinical trials is not unique to genitourinary trials. Approximately one in five cancer clinical trials fails to complete, most commonly due to poor accrual.
“The studies highlighted today present clinicians with a number of thought-provoking and potentially practice-changing implications,” said Charles J. Ryan, MD, moderator of today’s presscast, “Many of which can be integrated into our daily clinical practice and future research efforts.”
Genitourinary cancers include those of the prostate, kidney, bladder, and testis, as well as less common cancers such as those of the penis, ureters, and other urinary organs. In 2014, more than 385,000 people in the United States are expected to be diagnosed with genitourinary cancers, with an estimated 60,500 deaths. The most common genitourinary cancer is prostate cancer, which according to estimates, will be diagnosed in 233,000 men in the United States in 2014 and claim more than 29,400 lives.[i]
The 2014 Genitourinary Cancers Symposium is co-sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO).
About ASCO
The American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With nearly 35,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit www.asco.org. Patient-oriented cancer information is available at www.Cancer.Net.
[i] Siegel, R., Ma, J., Zou, Z. and Jemal, A. (2014), Cancer Statistics, 2014. CA: A Cancer Journal for Clinicians. doi: 10.3322/caac.21208
Contact
Kelly Baldwin
571-483-1365
American Society of Clinical Oncology (ASCO)
[ PRESS RELEASE ]